ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing. San Diego-based ADARx had previously expected to sell 21.9 million shares priced between $15 and $17. But the company’s …